Page 178 - CW E-Magazine (5-12-2023)

CPHI Barcelona 2023

in the coming months and we have also
new production capacity being built at
our site in Hyderabad,” said Mr. Luzeau.

The Seqens chief pointed out that
the India plans are part of the “regionali-
sation” trend. “We believe that our
customers are keen to consume mate-
rials that are sourced locally and it also
allows them to derisk supply chains.
Sequens is present in many countries
with strong presence in China and
India, and we will continue to develop
our businesses there even as we conti-
nue to progressively grow our European
business,” he said.

CPHI highlights
At CPHI Barcelona, the company
highlighted its entry into the cell and
gene therapy area through a recent “Through the SeqensUP, we look try, physics and biology can help find
acquisition in France of a brand from at improving the bioavailability of the solutions for our customers problems.
Novartis. The acquired CELL for API. This also includes all the equip- We want to be a provider of scientific
CURE’s cell and gene therapy deve- ment and technologies to fine tune the solution to our customers. We are also
lopment and production site at Les Ulis API, alone or with lipids polymers, to focussed on the macro trend of sustain-
(France) will be used as a CDMO site, optimise the activity of the API in the ability. The capacity of a company to
said Mr. Luzeau. body,” explained Mr. Eychenne-Baron. propose products or processes to its
customer that allow to reduce the envi-
The company also put the spotlight Speaking about industry trends ronmental footprint is very critical in
on its integrated offering called ‘Se- that would drive the company’s future our industry. We believe Seqens is very
qensUP’ by which the company seeks growth, Mr. Luzeau said, “We strongly well placed with a programme that
to empower the APIs of its customers. believe that the combination of chemis- we have set up almost 15 years ago.”
EXPANDING RANGE

C2 Pharma expands API portfolio with global

regulatory access

Ireland-based C2 Pharma has an- tor, our ability to successfully submit an additional contract manufacturing
nounced the expansion of global access and secure numerous regulatory filings partner, Hyderabad-based SMS Life-
to its portfolio of active pharmaceutical worldwide will enable us to better serve sciences. “This strengthens our manu-
ingredients (APIs) with new regulatory a truly global customer base in need of facturing network and accelerates the
submissions and approvals. Earlier this high-quality APIs,” said Mr. Andrew path towards bringing our R&D portfo-
year, the company received a CEP (certi- Badrot, CEO of C2 Pharma. The com- lio of ophthalmic products to the com-
ficate of suitability to the monographs pany is planning to launch oxybupro- mercial market,” said Dr. James Lawler,
of the European Pharmacopoeia) for caine (benoxinate hydrochloride) API General Manager of C2 Pharma.
cyclopentolate hydrochloride and re- in Q1-2024.
cently a C-DMF for digoxin, further The company exhibited at CPHI
consolidating its position in ophthalmic As it progressively expands the Barcelona with its affiliates, Logisi-
and niche APIs. “As we deepen portfolio of ophthalmic APIs, C2 tics4Pharma and ASM Research
our involvement in the ophthalmic sec- Pharma has signed an agreement with Chemicals.

178 Chemical Weekly December 5, 2023

Contents Index to Advertisers Index to Products Advertised